Popular Trials
5-alpha-reductase inhibitor
Dutasteride + Dietary Interventions for Prostate Cancer
This trial is testing if a special diet with fish oils and a prostate medication can slow down cancer in men with low-risk prostate cancer. The fish oils may reduce inflammation, and the medication lowers hormones that help cancer grow.
Corticosteroid
Abiraterone + Prednisone for Prostate Cancer
This trial will investigate whether adding abiraterone acetate + prednisone to the current standard of care (GnRH) can prolong the time until cancer growth is evident, as well as collecting safety information about this combination therapy.
Behavioral Intervention
EMPOWER Weight-Loss Program for Prostate Cancer
This trial will test if a weight loss program called EMPOWER can slow down prostate cancer in men whose cancer has returned after initial treatment. The goal is to delay the spread of cancer and avoid harsh treatments. Weight loss might help slow cancer growth, improving overall health without significant side effects.
AH-HA EHR Tool for Heart Health in Cancer Survivors
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Popular Filters
Trials for Adenocarcinoma Patients
Antiandrogen
Enzalutamide + ADT for Metastatic Prostate Cancer
This trial is testing whether a new drug, enzalutamide, is more effective than a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.
Chemotherapy
PT-112 Injection for Advanced Prostate Cancer
This trial is testing a new cancer drug, PT-112. It is in two parts, the first of which has finished enrolling. The second part is testing PT-112's safety and how well it works in patients with thymoma or thymic carcinoma, and in patients with metastatic castrate-resistant prostate cancer.
Corticosteroid
Apalutamide + Abiraterone Acetate + Prednisone for Prostate Cancer
This trial tests apalutamide added to a standard treatment for advanced prostate cancer. It targets patients whose cancer has spread and who haven't had chemotherapy. The treatment works by blocking and lowering male hormones that help cancer grow. Apalutamide has shown efficacy in treating different stages of prostate cancer.
Trials for Cancer Patients
Chemotherapy
PT-112 Injection for Advanced Prostate Cancer
This trial is testing a new cancer drug, PT-112. It is in two parts, the first of which has finished enrolling. The second part is testing PT-112's safety and how well it works in patients with thymoma or thymic carcinoma, and in patients with metastatic castrate-resistant prostate cancer.
CAR T-cell Therapy
P-PSMA-101 CAR-T Cells for Prostate Cancer
This trial tests a treatment where a patient's immune cells are modified to better fight advanced prostate and salivary gland cancers. The modified cells are reintroduced into the body to target and destroy cancer cells.
Cancer Vaccine
DNA Vaccines + Pembrolizumab for Metastatic Prostate Cancer
This trial will evaluate the use of one versus two DNA vaccines to treat prostate cancer that has spread and is no longer responding to hormone therapy. The hypothesis is that delivering two vaccines with a drug that blocks PD-1 will increase the percentage of patients experiencing an anti-tumor effect.
Monoclonal Antibodies
NPX267 for Cancer
This trial tests NPX267, an antibody drug that helps the immune system fight cancer by targeting a specific marker on cancer cells. It focuses on patients with certain cancers, including a type of lung cancer, to find a safe and effective dose. The study will monitor side effects and check how well the drug works against tumors.
Trials for Metastatic Patients
Antiandrogen
Enzalutamide + ADT for Metastatic Prostate Cancer
This trial is testing whether a new drug, enzalutamide, is more effective than a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.
Chemotherapy
PT-112 Injection for Advanced Prostate Cancer
This trial is testing a new cancer drug, PT-112. It is in two parts, the first of which has finished enrolling. The second part is testing PT-112's safety and how well it works in patients with thymoma or thymic carcinoma, and in patients with metastatic castrate-resistant prostate cancer.
Corticosteroid
Apalutamide + Abiraterone Acetate + Prednisone for Prostate Cancer
This trial tests apalutamide added to a standard treatment for advanced prostate cancer. It targets patients whose cancer has spread and who haven't had chemotherapy. The treatment works by blocking and lowering male hormones that help cancer grow. Apalutamide has shown efficacy in treating different stages of prostate cancer.
Phase 3 Trials
Antiandrogen
Enzalutamide + ADT for Metastatic Prostate Cancer
This trial is testing whether a new drug, enzalutamide, is more effective than a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.
Corticosteroid
Apalutamide + Abiraterone Acetate + Prednisone for Prostate Cancer
This trial tests apalutamide added to a standard treatment for advanced prostate cancer. It targets patients whose cancer has spread and who haven't had chemotherapy. The treatment works by blocking and lowering male hormones that help cancer grow. Apalutamide has shown efficacy in treating different stages of prostate cancer.
Trials With No Placebo
Antiandrogen
Enzalutamide + ADT for Metastatic Prostate Cancer
This trial is testing whether a new drug, enzalutamide, is more effective than a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.
Chemotherapy
PT-112 Injection for Advanced Prostate Cancer
This trial is testing a new cancer drug, PT-112. It is in two parts, the first of which has finished enrolling. The second part is testing PT-112's safety and how well it works in patients with thymoma or thymic carcinoma, and in patients with metastatic castrate-resistant prostate cancer.
View More Related Trials
Frequently Asked Questions
Introduction to prostate cancer
What are the top hospitals conducting prostate cancer research?
When it comes to cutting-edge clinical trials in prostate cancer, several top hospitals are making significant strides. Memorial Sloan Kettering Cancer Center in New york takes the lead with seven active trials focused on prostate cancer and an impressive history of 128 completed studies dedicated to this condition. Since recording its first trial back in 1994, this renowned institution has been at the forefront of prostate cancer research. Meanwhile, Dana-Farber Cancer Institute in Boston is also actively involved, currently conducting five clinical trials for prostate cancer and having accomplished a notable total of 89 previous studies since their inaugural trial in 1995.
Moving towards smaller-scale yet equally noteworthy centers, MidLantic Urology located in Bala-Cynwyd pursues four ongoing clinical investigations pertaining to prostate cancer while offering hope through pioneering research which began only a decade ago during2011.Across state lines lies Carolina Urologic Research Center situated at Myrtle Beach where they too undertake four active trials addressing prostrate cancers; their commendable contribution can be traced back eighteen years since initially recording their own trailblazing breakthrough way until2003.Meanwhile, Medical University of South carolina based out Charleston follows suit with four ongoing tests aimed specifically for prostrate ailments uncovering new possibilities by means of forty-seven previously held inquiries after starting fresh experimentation path from1994.
These institutions represent the collective commitment and dedication within the medical community as they strive towards better understanding and treatment options for those affected by prostate cancer. Each study brings us closer to potential breakthroughs that could transform lives worldwide. With these leading hospitals at the forefront, patients can find solace knowing that innovative treatments are being developed and tested every day to fight against one of the most prevalent cancers among men.
Which are the best cities for prostate cancer clinical trials?
When it comes to prostate cancer clinical trials, several cities stand out as leaders in research and development. New york, Los Angeles, Boston, Houston, and Omaha have a significant number of active trials focused on studying different treatments for prostate cancer. These trials investigate various cutting-edge interventions like Apalutamide, Pembrolizumab, Enzalutamide, and more. These cities provide individuals with access to innovative clinical trials that are paving the way for advancements in prostate cancer care and offering hope for improved outcomes.
Which are the top treatments for prostate cancer being explored in clinical trials?
[Prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) clinical trials are investigating several promising treatments to combat this disease. Leading the charge is pembrolizumab, which has shown great potential in four active trials and a total of 34 all-time prostate cancer trials since its introduction in 2014. Another contender, apalutamide, is also making waves with four ongoing trials and an impressive track record of 68 all-time prostate cancer studies since 2013. Not far behind is enzalutamide, currently involved in four active trials and boasting an extensive resume of 163 all-time prostate cancer studies dating back to 2005. Lastly, niraparib joins the ranks with two ongoing trials and a growing list of 13 all-time clinical investigations for prostate cancer since its listing in 2016. These innovative treatments offer hope for patients worldwide as researchers continue their quest towards finding effective solutions against prostate cancer
What are the most recent clinical trials for prostate cancer?
Exciting advancements in prostate cancer research have led to the development of several recent clinical trials. Among them, a Phase 1 trial is exploring dose optimization for prostate cancer treatment, aiming to refine and improve therapeutic strategies. In another Phase 2 trial, the efficacy and safety of Relugolix are being evaluated as a potential treatment option for prostate cancer. Additionally, an innovative Phase 1 trial is investigating the use of NPX267 therapy specifically tailored for prostate cancer patients. Lastly, a combined Phase 1/Phase 2 study explores the effectiveness of 67Cu-SAR-BBN in targeting prostate cancer cells. These groundbreaking trials offer hope for improved outcomes and more personalized approaches to treating this challenging disease.
What prostate cancer clinical trials were recently completed?
Several significant clinical trials for prostate cancer have recently been completed, demonstrating the continuous efforts to advance treatment options. Noteworthy among these is a trial sponsored by Clarity Pharmaceuticals Ltd., which concluded in April 2022, investigating the potential of 64Cu-SAR-bisPSMA. Similarly, Surface Oncology's study on SRF617 reached completion in January 2022, while a trial led by Ryan Kohlbrenner, MD focused on Catheterization was finalized in October 2021. These recent developments contribute to our understanding and progress towards more effective management of prostate cancer.